Charles River Laboratories said it will close its cell therapy contract development and manufacturing site in Hanover, Md., eliminating 20 positions, according to a state Worker Adjustment and Retraining Notification filing.

The closure is part of an ongoing restructuring at the Boston-based contract research organization, which has been reducing headcount and exiting select operations following a strategic review. The company said it determined that the Hanover facility was not a strategic fit and plans to transition client work to other sites by the second quarter of 2026.

Charles River said it is providing transition support to affected employees and may offer some opportunities to move into other roles within the company. The company has not said whether additional cuts to its cell therapy CDMO business are planned.

The Maryland layoffs follow other recent reductions. In November, Charles River laid off about 70 employees at its Wilmington, Mass., facility after shifting research model production to other sites.

Related News

Thermo Fisher Scientific also announced this week it will close a manufacturing facility in Franklin, Massachusetts, and eliminate up to 80 positions as it continues to pare its manufacturing footprint.